Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer

References

• Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. JCO. 2005;23:6207–6219.
   PubMed Web of Science ®Google Scholar
• Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small-cell lung cancer. Curr Oncol Rep. 2003;5:342–346.
   PubMedGoogle Scholar
• Welzel G, Fleckenstein K, Schaefer J, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys. 2008;72:1311–1318.
   PubMed Web of Science ®Google Scholar
• Li J, Bentzen SM, Li J, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008;71:64–70.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789–796.
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751.
   PubMed Web of Science ®Google Scholar
• Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol. 2008;184:251.
   PubMed Web of Science ®Google Scholar
• Rades D, Dziggel L, Haatanen T, et al. Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys. 2011;80:1122–1127.
   PubMed Web of Science ®Google Scholar
• Rades D, Dziggel L, Nagy V, et al. A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiother Oncol. 2013;108:123–127.
   PubMed Web of Science ®Google Scholar
• Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys. 2000;46:1155–1161.
   PubMed Web of Science ®Google Scholar
• Lorenzoni J, Devriendt D, Massager N, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004;60:218–224.
   PubMed Web of Science ®Google Scholar
• Serizawa T, Higuchi Y, Nagano O, et al. A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain Metastases. J Neurosurg. 2014;121:35–43.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510–514.
   PubMed Web of Science ®Google Scholar
• Villa S, Weber DC, Moretones C, et al. Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study. Radiat Oncol. 2011;6:23.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. JCO. 2012;30:419–425.
   PubMed Web of Science ®Google Scholar
• Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388:2004–2014.
   PubMed Web of Science ®Google Scholar
• Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1–v27.
   PubMed Web of Science ®Google Scholar
• Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;4:CD003869.
   PubMed Web of Science ®Google Scholar
• Blanco R, Maestu I, de la Torre MG, et al. A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol. 2015;26:451–463.
   PubMed Web of Science ®Google Scholar
• Gajra A, Jatoi A. Non-small-cell lung cancer in elderly patients: a discussion of treatment options. JCO. 2014;32:2562–2569.
   PubMed Web of Science ®Google Scholar
• Sulman EP, Ismaila N, Armstrong TS, et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. JCO. 2017;35:361–369.
   PubMed Web of Science ®Google Scholar
• Lutterbach J, Bartelt S, Stancu E, et al. Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3. Radiother Oncol. 2002;63:339–345.
   PubMed Web of Science ®Google Scholar
• Tsakonas G, De Petris L, Ekman S. Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies. Cancer Treat Rev. 2017;54:122–131.
   PubMed Web of Science ®Google Scholar
• Granone P, Margaritora S, D'Andrilli A, et al. Non-small cell lung cancer with single brain metastasis: the role of surgical treatment. Eur J Cardio-Thorac Surg. 2001;20:361–366.
   PubMed Web of Science ®Google Scholar
• Putora PM, Ess S, Panje C, et al. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis. 2015;32:143–149.
   PubMed Web of Science ®Google Scholar
• Harada H, Asakura H, Ogawa H, et al. Prognostic factors in patients with brain metastasis from non-small cell lung cancer treated with whole-brain radiotherapy. J Can Res Ther. 2016;12:267–270.
   PubMed Web of Science ®Google Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892–2911.
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18:4406–4414.
   PubMed Web of Science ®Google Scholar
• Schuler M, Wu YL, Hirsh V, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380–390.
   PubMed Web of Science ®Google Scholar
• Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. JCO. 2017;35:1070–1077.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15:387–395.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. ESMO, Madrid; 2017.
   Google Scholar